Clinical Trials Logo

Clinical Trial Summary

Introduction Bladder cancer is the most common malignancy involving the urinary system and the ninth most common malignancy worldwide. Urothelial carcinoma is accounts for approximately 90 percent of bladder cancers in the western world. In the United States, approximately 80,000 new cases and 17,000 deaths occur each year due to bladder cancer. Approximately 75% of patients present with superficial disease (Ta and T1), while 25% present with muscle invasive (T2 or greater) disease. Overall, 70% of treated tumors recur, with 30% of recurrent tumors progressing to muscle invasive disease. The majority of these patients have a recurrence after endoscopic resection, thus lifelong surveillance with periodically cystoscopy is recommended. Cystoscopy, which is the "gold standard" for the detection of bladder cancer, is an expensive and invasive procedure, and it also can miss a flat lesion, especially carcinoma in situ which is considered a high grade malignant condition, therefore better follow-up tools should be developed in order to address those issues. Voided urinary cytology is a useful noninvasive adjunct to cystoscopy due to its high specificity, more than 90%. Although it has a high sensitivity at detecting high-grade lesions, between 80 to 90%,, in low-grade its sensitivity is very low, between 20 to 50%. Amongst the non-muscle-invasive, low grade tumors will progress to muscle-invasive or metastatic cancer at approximately 10% and roughly a third of high-grade tumors progress, therefore, close monitoring and early detection of all lesions are important for management, and noninvasive tumor markers with high accuracy for the detection of all grades of urothelial carcinoma will significantly reduce patient cost, anxiety and morbidity. Cystoscopy in combination with cytology remains the most effective means of detecting bladder cancer. However, cystoscopy is an invasive procedure, and while cytology remains a useful method for detecting high grade tumors, its utility in detecting low grade tumors remains limited due to the lack of distinguishing cytological features between low grade disease and reactive processes. Currently there are several markers available or under investigation for the detection and monitoring/surveillance of bladder cancer, most of them have higher sensitivities, especially when used to identify low grade disease, but with lower specificities when compared to cytology. Furthermore, all of these tests must still be utilized in conjunction with cystoscopy findings. Recently, cell-free DNA (cfDNA) isolated from urine supernatant has been shown to have great potential in bladder cancer detection and surveillance. Bladder cancer exhibits unique genetic features that can be identified from sequencing and expression of cfDNA. Aim of study: The aim of this study is to establish a method for a personalized urinary biomarker with the usage of well explored urothelail cancer genetic mutations in urine cfDNA, for the detection of bladder cancer presence.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05467267
Study type Observational
Source Ziv Hospital
Contact Ran Katz, MD
Phone +972-4-8629775
Email rank@ziv.gov.il
Status Not yet recruiting
Phase
Start date August 2022
Completion date August 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Completed NCT05540847 - Comparison of Interfascial Injection Versus Subpectineal Injection on Ultrasound-guided Obturator Nerve Block N/A
Terminated NCT00249301 - A Study of MLN8054 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06167356 - Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
Terminated NCT01200992 - Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer Phase 3
Recruiting NCT04839029 - Bipolar Versus Mono-polar Needlescopic En Bloc TUR-BT N/A
Active, not recruiting NCT03138824 - Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC N/A
Completed NCT03013894 - Confocal Laser Endomicroscopy in the Lower Urinary Tract
Recruiting NCT06416319 - Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct) N/A
Completed NCT00722553 - Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder Phase 2
Active, not recruiting NCT04167631 - Can VI-RADS/ADC Accurately Stage Bladder Cancer?? N/A
Completed NCT03458598 - Pre-Operative Single Shot Rectus Sheath Block N/A
Recruiting NCT04075305 - The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Not yet recruiting NCT05134623 - Smurf2 Gene Expression in Urinary Tract Tumors
Completed NCT04200963 - A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma Phase 1
Recruiting NCT05022160 - Preventing Catheter Related Bladder Discomfort (CRBD) With Bilateral Pudendal Nerve Block Early Phase 1
Completed NCT03591367 - The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation N/A
Terminated NCT03335059 - Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. Phase 3
Recruiting NCT05027412 - En Bloc TURBT With Collins Loop vs Conventional TURBT N/A
Recruiting NCT04784507 - En-Bloc Resection of Bladder Tumors Phase 2